Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rank in Stocks #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Share Price
$23.57
Last synced: 2026-08-20
Market Cap
$51.76M
Change (1 day)
-0.08%
Change (1 year)
289.59%
Country
US
Trade Apollomics, Inc. (APLM)

Category

Number of shares outstanding for Apollomics, Inc. (APLM)
Number of shares outstanding as of August 2026: 0
According to Apollomics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Apollomics, Inc. (APLM) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
396.00M -
US